247 related articles for article (PubMed ID: 35980666)
1. Outcomes Among Patients With Mucosal Head and Neck Squamous Cell Carcinoma Treated With Checkpoint Inhibitors.
Hobday SB; Brody RM; Kriegsman B; Basu D; Newman J; Cohen RB; Lukens JN; Singh A; D'Avella CA; Sun L
JAMA Otolaryngol Head Neck Surg; 2022 Oct; 148(10):918-926. PubMed ID: 35980666
[TBL] [Abstract][Full Text] [Related]
2. Epidermal growth factor receptor targeted therapy in stages III and IV head and neck cancer.
Cripps C; Winquist E; Devries MC; Stys-Norman D; Gilbert R;
Curr Oncol; 2010 Jun; 17(3):37-48. PubMed ID: 20567625
[TBL] [Abstract][Full Text] [Related]
3. Evaluation of Concomitant Systemic Treatment in Older Adults With Head and Neck Squamous Cell Carcinoma Undergoing Definitive Radiotherapy.
Rühle A; Marschner S; Haderlein M; Fabian A; Weymann M; Behrens M; Senger C; Dickstein DR; Kraft J; von der Grün J; Chen E; Aquino-Michaels T; Domschikowski J; Bickel A; Altay-Langguth A; Kalinauskaite G; Lewitzki V; Ferentinos K; Zamboglou C; Schnellhardt S; Haehl E; Spohn SKB; Gkika E; Zöller D; Guckenberger M; Budach V; Belka C; Bakst R; Mayer A; Schmidberger H; Grosu AL; Balermpas P; Stromberger C; Nicolay NH
JAMA Netw Open; 2023 Feb; 6(2):e230090. PubMed ID: 36808242
[TBL] [Abstract][Full Text] [Related]
4. Afatinib versus methotrexate as second-line treatment in patients with recurrent or metastatic squamous-cell carcinoma of the head and neck progressing on or after platinum-based therapy (LUX-Head & Neck 1): an open-label, randomised phase 3 trial.
Machiels JP; Haddad RI; Fayette J; Licitra LF; Tahara M; Vermorken JB; Clement PM; Gauler T; Cupissol D; Grau JJ; Guigay J; Caponigro F; de Castro G; de Souza Viana L; Keilholz U; Del Campo JM; Cong XJ; Ehrnrooth E; Cohen EE;
Lancet Oncol; 2015 May; 16(5):583-94. PubMed ID: 25892145
[TBL] [Abstract][Full Text] [Related]
5. Initial analysis of the synergy of programmed cell death-1 (PD-1) inhibitor and concurrent chemoradiotherapy treatment for recurrent/metastatic head and neck squamous cell carcinoma patients.
Li L; Chen L; Yan L; Guo Y; Li F; Fan M; Lan M; Lai X; Zhou J; Huang Y; Xu P; Lang J; Feng M
Radiat Oncol; 2023 Jul; 18(1):109. PubMed ID: 37403098
[TBL] [Abstract][Full Text] [Related]
6. Survival predictors and outcomes of patients with recurrent and/or metastatic head and neck cancer treated with chemotherapy plus cetuximab as first-line therapy: A real-world retrospective study.
Pontes F; Garcia AR; Domingues I; João Sousa M; Felix R; Amorim C; Salgueiro F; Mariano M; Teixeira M
Cancer Treat Res Commun; 2021; 27():100375. PubMed ID: 33882378
[TBL] [Abstract][Full Text] [Related]
7. Clinical outcomes of immune checkpoint inhibitors for patients with recurrent or metastatic head and neck cancer: real-world data in Korea.
Kim H; Kwon M; Kim B; Jung HA; Sun JM; Lee SH; Park K; Ahn MJ
BMC Cancer; 2020 Aug; 20(1):727. PubMed ID: 32758163
[TBL] [Abstract][Full Text] [Related]
8. Tumor Histological Grade and Immunotherapy Response in Patients With Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma.
Alkhatib HH; Maroun CA; Amin N; Zhu G; Guller M; Herberg ME; Wu ES; Seiwert TY; Rooper LM; Eisele DW; Fakhry C; Pardoll D; Mandal R
JAMA Otolaryngol Head Neck Surg; 2022 Jun; 148(6):540-546. PubMed ID: 35482301
[TBL] [Abstract][Full Text] [Related]
9. Outcomes and Biomarkers of Immune Checkpoint Inhibitor Therapy in Patients with Refractory Head and Neck Squamous Cell Carcinoma: KCSG HN18-12.
Lee YG; Chang H; Keam B; Chun SH; Park J; Park KU; Shin SH; An HJ; Lee KE; Lee KW; Kim HR; Kim SB; Ahn MJ; Hwang IG
Cancer Res Treat; 2021 Jul; 53(3):671-677. PubMed ID: 33285051
[TBL] [Abstract][Full Text] [Related]
10. Patterns of Treatment Failure and Postrecurrence Outcomes Among Patients With Locally Advanced Head and Neck Squamous Cell Carcinoma After Chemoradiotherapy Using Modern Radiation Techniques.
Leeman JE; Li JG; Pei X; Venigalla P; Zumsteg ZS; Katsoulakis E; Lupovitch E; McBride SM; Tsai CJ; Boyle JO; Roman BR; Morris LGT; Dunn LA; Sherman EJ; Lee NY; Riaz N
JAMA Oncol; 2017 Nov; 3(11):1487-1494. PubMed ID: 28542679
[TBL] [Abstract][Full Text] [Related]
11. Improved survival of patients with human papillomavirus-positive head and neck squamous cell carcinoma in a prospective clinical trial.
Fakhry C; Westra WH; Li S; Cmelak A; Ridge JA; Pinto H; Forastiere A; Gillison ML
J Natl Cancer Inst; 2008 Feb; 100(4):261-9. PubMed ID: 18270337
[TBL] [Abstract][Full Text] [Related]
12. Global treatment patterns and outcomes among patients with recurrent and/or metastatic head and neck squamous cell carcinoma: Results of the GLANCE H&N study.
Grünwald V; Chirovsky D; Cheung WY; Bertolini F; Ahn MJ; Yang MH; Castro G; Berrocal A; Sjoquist K; Kuyas H; Auclair V; Guillaume X; Joo S; Shah R; Harrington K;
Oral Oncol; 2020 Mar; 102():104526. PubMed ID: 31978755
[TBL] [Abstract][Full Text] [Related]
13. Association of Human Papillomavirus Status at Head and Neck Carcinoma Subsites With Overall Survival.
Li H; Torabi SJ; Yarbrough WG; Mehra S; Osborn HA; Judson B
JAMA Otolaryngol Head Neck Surg; 2018 Jun; 144(6):519-525. PubMed ID: 29801040
[TBL] [Abstract][Full Text] [Related]
14. Cetuximab-Based vs Carboplatin-Based Chemoradiotherapy for Patients With Head and Neck Cancer.
Sun L; Candelieri-Surette D; Anglin-Foote T; Lynch JA; Maxwell KN; D'Avella C; Singh A; Aakhus E; Cohen RB; Brody RM
JAMA Otolaryngol Head Neck Surg; 2022 Nov; 148(11):1022-1028. PubMed ID: 36136306
[TBL] [Abstract][Full Text] [Related]
15. Pembrolizumab alone or with chemotherapy versus cetuximab with chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-048): a randomised, open-label, phase 3 study.
Burtness B; Harrington KJ; Greil R; Soulières D; Tahara M; de Castro G; Psyrri A; Basté N; Neupane P; Bratland Å; Fuereder T; Hughes BGM; Mesía R; Ngamphaiboon N; Rordorf T; Wan Ishak WZ; Hong RL; González Mendoza R; Roy A; Zhang Y; Gumuscu B; Cheng JD; Jin F; Rischin D;
Lancet; 2019 Nov; 394(10212):1915-1928. PubMed ID: 31679945
[TBL] [Abstract][Full Text] [Related]
16. Evaluation of Proton Therapy Reirradiation for Patients With Recurrent Head and Neck Squamous Cell Carcinoma.
Lee A; Woods R; Mahfouz A; Kitpanit S; Cartano O; Mohamed N; Youssef I; Marqueen K; Sine K; Mah D; Neal B; Zakeri K; Kang JJ; Riaz N; Yu Y; McBride SM; Chen LD; Tsai CJ; Gelblum DY; Press RH; Michel LS; Sherman EJ; Pfister D; Dunn LA; Ho AL; Fetten J; Wong RJ; Boyle JO; Singh B; Cracchiolo JR; Ganly I; Cohen MA; Lee NY
JAMA Netw Open; 2023 Jan; 6(1):e2250607. PubMed ID: 36689229
[TBL] [Abstract][Full Text] [Related]
17. Clinical Outcomes of Cetuximab and Paclitaxel after Progression on Immune Checkpoint Inhibitors in Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma.
Suzuki S; Toyoma S; Kawasaki Y; Koizumi K; Iikawa N; Shiina K; Endo T; Abe T; Kouga T; Yamada T
Medicina (Kaunas); 2021 Oct; 57(11):. PubMed ID: 34833369
[No Abstract] [Full Text] [Related]
18. Real-world time on treatment with immuno-oncology therapy in recurrent/metastatic head and neck squamous cell carcinoma.
Ramakrishnan K; Liu Z; Baxi S; Chandwani S; Joo S; Chirovsky D
Future Oncol; 2021 Aug; 17(23):3037-3050. PubMed ID: 34044594
[TBL] [Abstract][Full Text] [Related]
19. Real-world treatment patterns and outcomes among individuals receiving first-line pembrolizumab therapy for recurrent/metastatic head and neck squamous cell carcinoma.
Black CM; Hanna GJ; Wang L; Ramakrishnan K; Goto D; Turzhitsky V; Hair GM
Front Oncol; 2023; 13():1160144. PubMed ID: 37284189
[TBL] [Abstract][Full Text] [Related]
20. Cisplatin and fluorouracil with or without panitumumab in patients with recurrent or metastatic squamous-cell carcinoma of the head and neck (SPECTRUM): an open-label phase 3 randomised trial.
Vermorken JB; Stöhlmacher-Williams J; Davidenko I; Licitra L; Winquist E; Villanueva C; Foa P; Rottey S; Skladowski K; Tahara M; Pai VR; Faivre S; Blajman CR; Forastiere AA; Stein BN; Oliner KS; Pan Z; Bach BA;
Lancet Oncol; 2013 Jul; 14(8):697-710. PubMed ID: 23746666
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]